Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Timing and Impact of Posttreatment PET/CT After First 6 Months on Patient Management and Outcomes in Oropharyngeal Squamous Cell Carcinoma.

Publication ,  Conference
You, H; Xi, Y; Moore, W; Sher, D; Sanli, Y; Subramaniam, RM
Published in: AJR Am J Roentgenol
May 2019

OBJECTIVE. The objective of this study was to investigate the impact of PET/CT on patient management and outcomes of oropharyngeal squamous cell carcinoma (OPSCC) after the first 6 months following treatment. MATERIALS AND METHODS. We retrospectively identified patients with OPSCC who underwent chemoradiation therapy and had at least 2 years of posttreatment follow-up. Patients were grouped on the basis of whether they underwent PET/CT, as a result of clinical suspicion of recurrence or routine follow-up, in the last 18 months of the 2-year posttreatment period (experimental group) or not (control group). Association between PET/CT use and change in management was tested using chi-square analysis. Survival analyses were performed with Cox and Kaplan-Meier analyses. RESULTS. In total, 149 patients underwent 294 PET/CT studies in the 2-year follow-up period. Eighty-three patients (55.7%) underwent PET/CT in the last 18 months of the 2 years. This group underwent 223 PET/CT studies, 22 (9.9%) of which were positive. Sixteen of the 22 (72.7%) changed management. Sixty-six patients (44.3%) did not undergo PET/CT in the last 18 months. This group underwent 71 PET/CT studies, six (8.5%) of which were positive. Two of the six studies (33.3%) changed management. Of first-time positive PET/CT studies in the last 18 months, five of nine (55.6%) were performed 6-12 months after treatment. PET/CT in the last 18 months was positively associated with change in management (odds ratio, 4.88; p = 0.02). Patients with positive PET/CT findings had worse overall survival (hazard ratio [HR], 31.6; p < 0.0001) and progression-free survival (HR, 40.8; p < 0.0001). CONCLUSION. PET/CT in the last 18 months of the 2-year posttreatment period impacted patient management. Most first-time positive PET/CT studies in the last 18 months of the 2 years were performed 6-12 months after treatment.

Duke Scholars

Published In

AJR Am J Roentgenol

DOI

EISSN

1546-3141

Publication Date

May 2019

Volume

212

Issue

5

Start / End Page

1142 / 1147

Location

United States

Related Subject Headings

  • Nuclear Medicine & Medical Imaging
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
You, H., Xi, Y., Moore, W., Sher, D., Sanli, Y., & Subramaniam, R. M. (2019). Timing and Impact of Posttreatment PET/CT After First 6 Months on Patient Management and Outcomes in Oropharyngeal Squamous Cell Carcinoma. In AJR Am J Roentgenol (Vol. 212, pp. 1142–1147). United States. https://doi.org/10.2214/AJR.18.20619
You, Helena, Yin Xi, William Moore, David Sher, Yasemin Sanli, and Rathan M. Subramaniam. “Timing and Impact of Posttreatment PET/CT After First 6 Months on Patient Management and Outcomes in Oropharyngeal Squamous Cell Carcinoma.” In AJR Am J Roentgenol, 212:1142–47, 2019. https://doi.org/10.2214/AJR.18.20619.
You H, Xi Y, Moore W, Sher D, Sanli Y, Subramaniam RM. Timing and Impact of Posttreatment PET/CT After First 6 Months on Patient Management and Outcomes in Oropharyngeal Squamous Cell Carcinoma. In: AJR Am J Roentgenol. 2019. p. 1142–7.
You, Helena, et al. “Timing and Impact of Posttreatment PET/CT After First 6 Months on Patient Management and Outcomes in Oropharyngeal Squamous Cell Carcinoma.AJR Am J Roentgenol, vol. 212, no. 5, 2019, pp. 1142–47. Pubmed, doi:10.2214/AJR.18.20619.
You H, Xi Y, Moore W, Sher D, Sanli Y, Subramaniam RM. Timing and Impact of Posttreatment PET/CT After First 6 Months on Patient Management and Outcomes in Oropharyngeal Squamous Cell Carcinoma. AJR Am J Roentgenol. 2019. p. 1142–1147.

Published In

AJR Am J Roentgenol

DOI

EISSN

1546-3141

Publication Date

May 2019

Volume

212

Issue

5

Start / End Page

1142 / 1147

Location

United States

Related Subject Headings

  • Nuclear Medicine & Medical Imaging
  • 3202 Clinical sciences
  • 1103 Clinical Sciences